
Glumetinib
CAS No. 1642581-63-2
Glumetinib ( SCC244 | SCC 244 )
产品货号. M12497 CAS No. 1642581-63-2
Glumetinib (SCC 244) 是一种新型有效且高选择性的 c-Met 激酶抑制剂,IC50 为 0.42 nM。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥915 | 有现货 |
![]() ![]() |
10MG | ¥1401 | 有现货 |
![]() ![]() |
25MG | ¥2365 | 有现货 |
![]() ![]() |
50MG | ¥3540 | 有现货 |
![]() ![]() |
100MG | ¥5233 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Glumetinib
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Glumetinib (SCC 244) 是一种新型有效且高选择性的 c-Met 激酶抑制剂,IC50 为 0.42 nM。
-
产品描述Glumetinib (SCC 244)?is a novel potent and highly selective inhibitor of c-Met kinase with IC50 of 0.42 nM; displays high selectivity versus 312 other tested protein kinases; profoundly and specifically inhibits c-Met signal transduction and suppresses the c-Met-dependent neoplastic phenotype of tumor and endothelial cells; exhibits robust in vivo antitumor activity in NSCLC and hepatocellular carcinoma models.Lung Cancer Preclinical(In Vitro):Glumetinib (SCC244) (0-10 nM; 72 hours) elicits selective and profound effects against c-Met–driven cancer cell proliferation.Glumetinib (0-50 nM; 24 hours) induces G1–S phase cell-cycle arrest in c-Met–addicted human cancer cells.(In Vivo):Glumetinib (2.5-10 mg/kg; p.o.; once daily for 2-3 weeks) significantly inhibits c-Met–driven tumor growth in cancer CDX models.Glumetinib shows significant antitumor efficiency in NSCLC and HCC tumor PDX models with MET aberration.
-
体外实验Glumetinib (SCC244) (0-10 nM; 72 hours) elicits selective and profound effects against c-Met–driven cancer cell proliferation.Glumetinib (0-50 nM; 24 hours) induces G1–S phase cell-cycle arrest in c-Met–addicted human cancer cells. Cell Proliferation Assay Cell Line:EBC-1, SNU-5, MKN-45, BaF3/TPR-Met cells Concentration:0-10 nM Incubation Time:72 hours Result:Specifically and potently inhibited proliferation of c-Met–addicted human cancer cells (IC50 ranging 0.5 to 2.45 nM for EBC-1, SNU-5, MKN-45, BaF3/TPR-Met cells ).Cell Cycle AnalysisCell Line:EBC-1 and MKN-45 cells Concentration:0-50 nM Incubation Time:24 hours Result:Consistently induced G1–S cell-cycle arrest.
-
体内实验Glumetinib (2.5-10 mg/kg; p.o.; once daily for 2-3 weeks) significantly inhibits c-Met–driven tumor growth in cancer CDX models.Glumetinib shows significant antitumor efficiency in NSCLC and HCC tumor PDX models with MET aberration. Animal Model:Female nude mice (4-6 weeks old) (MKN-45 model) Dosage:10, 5, 2.5 mg/kg Administration:P.o.; once daily for 2-3 weeks Result:Significantly inhibited tumor growth with inhibitory rates of 99.3%, 88.6%, and 63.6% at doses of 10, 5, and 2.5 mg/kg, respectively.
-
同义词SCC244 | SCC 244
-
通路Angiogenesis
-
靶点c-Met/HGFR
-
受体c-Met
-
研究领域Cancer
-
适应症Lung Cancer
化学信息
-
CAS Number1642581-63-2
-
分子量459.488
-
分子式C21H17N9O2S
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESO=S(N1N=CC2=NC=C(C3=CN(C)N=C3)C=C21)(C4=CN=C5C=CC(C6=CN(C)N=C6)=CN54)=O
-
化学全称6-(1-Methyl-1H-pyrazol-4-yl)-1-[[6-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl]sulfonyl]-1H-pyrazolo[4,3-b]pyridine
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Ai J, et al. Mol Cancer Ther. 2017 Dec 13. pii: molcanther.0368.2017.
产品手册




关联产品
-
SGX-523
SGX-523 是一种有效的、选择性 ATP 竞争性 MET 受体酪氨酸激酶抑制剂,IC50 为 4 nM。
-
SU11274
SU11274 (PKI-SU11274) 是一种有效的、选择性的、ATP 竞争性的 c-Met 激酶抑制剂,IC50 为 20 nM。
-
Rilotumumab
Rilotumumab (AMG 102) 是一种 anti-HGF (抗肝细胞生长因子) 的单克隆抗体,抑制 HGF/MET 驱动的信号传导。Rilotumumab 具有抗肿瘤活性,可用于去势抵抗性前列腺癌 (CRPC) 和实体瘤的研究。